论文部分内容阅读
目的研究肿瘤标志物检验用于诊断肺癌的临床价值。方法抽取肺癌患者80例和同期体检健康人员100例为健康对照。所有参与研究人员采集空腹静脉血检测肿瘤标志物包括:癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、糖蛋白(CA125)和细胞角蛋白(Cyfra21-1),并对检验结果进行统计学分析。结果研究组患者血清中肿瘤标志物,CEA、NSE、CA125以及Cyfra21-1的含量均显著高于对照组患者(P<0.05)。结论肺癌患者血清肿瘤标志物CEA、NSE、CA125和Cyfra21-1含量显著升高,可以作为诊断肺癌的临床依据。
Objective To study the clinical value of tumor marker test in the diagnosis of lung cancer. Methods Totally 80 lung cancer patients and 100 healthy people in the same period were selected as healthy controls. All participating researchers collected fasting venous blood for detection of tumor markers including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), glycoprotein (CA125) and cytokeratin (Cyfra21-1) Results were statistically analyzed. Results The levels of tumor markers, CEA, NSE, CA125 and Cyfra21-1 in the study group were significantly higher than those in the control group (P <0.05). Conclusion The levels of serum tumor markers CEA, NSE, CA125 and Cyfra21-1 in patients with lung cancer are significantly increased, which may be used as a clinical basis for diagnosis of lung cancer.